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Blocking programmed cell death 1 in combination
with adoptive cytotoxic T-cell transfer eradicates chronic
myelogenous leukemia stem cells
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In chronic myelogenous leukemia (CML), quiescent, self-
renewing leukemia stem cells (LSCs) are resistant against
chemotherapy and speciﬁc tyrosine kinase inhibitors (TKIs).1,2
During treatment, LSCs remain in the bone marrow (BM) and
cause disease relapse after drug discontinuation.3,4 Moreover,
persisting LSCs may acquire BCR-ABL1 mutations that interfere
with TKI binding or accumulate genetic alterations that lead to
blast crisis. T-cell-based immunotherapy has been shown to be
efﬁcacious in solid tumors and in leukemia5 and allogeneic stem
cell transplantation and donor lymphocyte infusions (DLIs) are
the only curative treatments in CML.6 However, LSCs evolved
several mechanisms to escape cytotoxic CD8+ T cells (CTLs)-
mediated immune attack.4 We recently demonstrated that
interferon gamma (IFNγ) secreted by adoptively transferred
leukemia-speciﬁc CTLs in a situation with high leukemia load
even increased the numbers of LSCs while more differentiated
leukemia cells were efﬁciently eliminated.7 Why LSCs are
selectively resistant against elimination by CTLs is unknown.
One major immune escape mechanism of tumor cells is the
dysregulation of T-cell inhibitory pathways, so-called immune
checkpoints.1 Indeed, CML cells express T-cell inhibitory ligands
such as programmed cell death ligand 1 (PD-L1), light and herpes
virus entry mediator and high expression of PD-L1 on CD34+ CML
cells is a negative prognostic factor.7–10 Here, we addressed the
expression of PD-L1 in the differentiation hierarchy of BM CML
stem/progenitor cell subsets.4,11,12 CML was induced by retroviral
transduction of BM from 5-ﬂuorouracil-treated H8 transgenic
mice13 with BCR-ABL1-GFP, followed by transfer to sublethally
irradiated C57BL/6 (BL/6) recipient mice (H8 CML).7 In this
setting, BCR-ABL1-GFP+ leukemia cells express the glycoprotein
epitope gp33 of lymphocytic choriomenigitis virus (LCMV) under
the control of a major histocompatibility complex-I (MHC-I)
promoter as model leukemia antigen. Nineteen days after
transplantation, BM BCR-ABL1-GFP+ granulocyte–monocyte pro-
genitors (GMPs), common-myeloid progenitors (CMPs), multi-
potent progenitor 2 (MPP2s), MPP1s, short-term (ST)- and long-
term (LT)-LSCs expressed PD-L1 (Figures 1a and b). Interestingly,
LSC subsets (MPPs, ST- and LT-LSCs) expressed higher levels of
PD-L1 than leukemia progenitors (GMPs and CMPs), with highest
expression on LT-LSCs (Figure 1a and data not shown). To
determine PD-L1 expression after adoptive CTL transfer (adTf),
H8 CML mice were treated with LCMV-gp33-speciﬁc TCR
transgenic (p14) effector CTLs. CTL transfer resulted in an
upregulation of PD-L1 on CML stem/progenitor cells (Figures
1a and b). PD-L1 was more upregulated on LSC subsets than on
leukemia progenitors, with a mean ﬂuorescence intensity
increase of ~ 4-fold in LT-LSCs (Figure 1b). Treatment with
IFNγ-deﬁcient CTLs (p14xIFNγ−/−) did not increase PD-L1 expres-
sion compared with untreated controls, indicating that PD-L1
upregulation was mediated by CTL-secreted IFNγ (Figure 1b). In
accordance with our ﬁndings, IFNγ has been shown to induce
PD-L1 expression on different types of cancer including
leukemia.1 One reason for the observed differences in PD-L1
expression on LSC subsets and leukemia progenitors after
transfer of p14 CTLs may be a different sensitivity to IFNγ.
Therefore, we examined IFNγ receptor (IFNγR) expression on
total LSCs (lin−c-kithiSca-1+) and leukemia progenitors (lin−c-
kit+Sca-1−). LSCs expressed higher levels of IFNγR than leukemia
progenitors (Figure 1c).
T-cell inhibitory surface receptors such as PD-1, natural killer cell
antigen 2B4 and lymphocyte activation gene-3 (LAG-3) are
commonly upregulated on CD8+ T cells upon activation and are
frequently overexpressed on tumor-inﬁltrating T cells.1 We there-
fore assessed the expression of these receptors on BM CD8+ T cells
after adTf of p14 CTLs. BM-inﬁltrating leukemia-speciﬁc CTLs
expressed high levels of PD-1 while 2B4 and LAG-3 expression was
only marginal (Figure 1d).
These results indicate that PD-L1 is constitutively expressed on
LSCs and leukemia progenitors, is further upregulated in response
to effector CTL-secreted IFNγ and may protect LSCs from
CTL-mediated elimination.
To test this, we analyzed whether genetic or therapeutic
blockade of PD-1 signaling during p14 CTL transfer allows
eradicating LSCs in vivo. Seventeen days after leukemia induction,
H8 CML mice with comparable leukemia burden (109±13 BCR-
ABL1-GFP+Gr-1+ granulocytes/μl blood) were randomized to control
treatment with vehicle (Veh), p14 CTLs (p14), a blocking αPD-1
monoclonal antibody (mAb; αPD-1, clone RMP1–14), treatment with
PD-1-deﬁcient p14 CTLs (p14xPD-1−/−) or p14 CTLs in combination
with αPD-1 (αPD-1/p14). p14xPD-1−/− and αPD-1/p14 treatments
reduced leukemia burden as indicated by smaller spleen size and
lower numbers of leukemia progenitors in the BM compared with
Veh, αPD-1 and p14 CTL-treated groups (Figures 1e–g). As reported
previously,7 p14 CTL transfer increased LSC numbers (Figures 1h
and i). Importantly, PD-1 blocking during adTf of p14 CTLs
signiﬁcantly reduced LSCs and resulted in fewer BCR-ABL1-GFP+
methylcellulose colonies from lin− BM cells (Figures 1h and i). In
CML, only LT-LSCs are able to propagate the disease in vivo,
whereas other LSC subsets and more differentiated progenitors are
able to form colonies in vitro.12 To investigate if the reduced
numbers of LSCs as deﬁned immunophenotypically by FACS or
functionally in vitro actually accounted for reduced numbers of
leukemia-initiating cells in vivo, we secondarily transplanted BM
cells from H8 CML mice of all treatment groups into lethally
irradiated BL/6 mice. Animals transplanted with BM from p14 CTL-
treated CML mice succumbed signiﬁcantly faster to the disease
than mice after transplantation of Veh-treated control CML BM.7 In
contrast, mice transplanted with BM from αPD-1-treated H8 CML
mice survived signiﬁcantly longer than controls, but the prolonga-
tion of survival was marginal. Importantly, only PD-1 blockade
during transfer of p14 CTLs in primary CML mice substantially
prolonged the survival of secondary recipient mice, indicating that
this treatment indeed targets leukemia-initiating cells (Figure 1j).
However, LSCs were not eliminated completely within 2 days after
treatment (Figures 1h–j).
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To assess the therapeutic role of PD-1 blockade during adTf in
more detail, H8 CML mice (161 ± 16 BCR-ABL1-GFP+Gr-1+ granu-
locytes/μl blood) were treated as described and disease
progression and survival were monitored. Transfer of p14 CTLs
or treatment with αPD-1 mAb alone did not improve survival. In
contrast, PD-1 blockade during CTL transfer led to long-term
survival of all H8 CML mice (Figure 1k). These data suggest that
LSCs were either eliminated or effectively controlled by this
treatment.
Therefore, we next analyzed if the surviving mice had
eliminated LSCs 73 days after adTf of CTLs. Some mice harbored
residual disease as indicated by low percentages of BCR-ABL1-
GFP+Gr-1+ granulocytes in peripheral blood (Figure 1l). In addition,
lin− BM cells from surviving animals still formed few BCR-ABL1+-
GFP+ colonies (Figure 1m). To functionally investigate whether
leukemia-initiating cells had persisted, we transferred BM cells
from surviving mice into lethally irradiated secondary BL/6
recipients. Only 3 out of 10 secondary recipients developed a
CML, whereas the other 7 survived long term without signs of
leukemia, as analyzed by FACS of peripheral blood (Figure 1n and
data not shown). These results indicate that one single transfer of
leukemia-speciﬁc effector CTLs in combination with genetic
deletion or mAb blocking of PD-1 eliminated the disease-
initiating LSCs in a majority of animals treated at a late stage of
the disease.
LCMV-gp33 was used in the ﬁrst experiments as a model
leukemia antigen that allows an in-depth characterization of T-cell
responses. To analyze whether our ﬁndings are of relevance in a
more physiological setting, we made use of an MHC-I mismatch
model (Balb/c × BL/6 F1-generation, CB/6) that has been used to
analyze the effect of human leukocyte antigen-mismatched DLIs.14
MHC-I in BL/6 mice consists of H2-Kb/Db; Balb/c mice express H2-
Kd/Dd. CB/6 mice consequently express H2-Kbd/Dbd. CB/6 BM was
retrovirally transduced with BCR-ABL1-GFP before transfer into
sublethally irradiated CB/6 recipient mice (CB/6 CML). In this
setting, the leukemia cells as well as the endogenous non-
malignant cells express H2-Kbd/Dbd.15 CB/6 CML mice were then
treated 11 days after CML induction with Veh, MACS-puriﬁed naive
CD8+ T cells from BL/6 mice (CD8, H2-Kb/Db), a blocking αPD-1
mAb (αPD-1) or BL/6 CD8+ T cells and αPD-1 mAb in combination
(αPD-1/CD8). Treatment effects on the different LSC subsets in
CB/6 CML mice were analyzed 10 days later. CD8 transfer
increased numbers of LSC subsets in BM compared with
Veh-treated controls (Figures 2a–g), indicating that similarly to
the transfer of gp33-speciﬁc effector CTLs (Figures 1h and i),7
allogeneic CD8+ T cells induce expansion of LSCs. In contrast,
αPD-1/CD8 treatment signiﬁcantly reduced the numbers of all LSC
subsets (Figures 2a–e). This ﬁnding was conﬁrmed functionally by
assessing BCR-ABL1-GFP+ colony formation (Figure 2f) as well as
by secondary transplantations (Figure 2g).
Furthermore, CD8 and αPD-1/CD8 treatment reduced leukemia
burden in the peripheral blood compared with Veh- and αPD-1-
treated mice (Figure 2h). CD8 or αPD-1 treatment alone did not
result in a survival advantage when compared with Veh-treated
controls. In contrast, the majority of CB/6 CML mice that received
αPD-1/CD8 combination treatment survived long term (Figure 2i).
Surviving mice still harbored some residual disease as indicated
by BCR-ABL1-GFP+ methylcellulose colony formation of lin− BM
(Figure 2j). However, although capable of colony formation, these
residual leukemia cells were unable to induce CML after
transplantation of BM into lethally irradiated secondary recipients
(Figure 2k), indicating that the leukemia-initiating cells had been
eliminated.
T-cell therapy is very efﬁcacious in a setting with low
leukemia load. This has been documented by clinical data in
CML but also experimentally in our CML model.6,7 However, in a
setting of high leukemia load without prior cytoreduction,
LT-LSCs upregulate PD-L1 in response to IFNγ secreted by
leukemia-speciﬁc or allogeneic CTLs during adTf and thereby
escape CTL-mediated killing. Together with the increased
proliferation of LSCs induced by CTL-secreted IFNγ7 this results
in increased LSC numbers and represents a major obstacle for
T-cell immunotherapy of CML. We now show that blocking
PD-1 in combination with T-cell immunotherapy efﬁciently
eliminates the disease-initiating LSCs even in a therapeutical
setting with high leukemia load. In contrast, αPD-1 treatment
alone was largely inefﬁcacious. This may be because of the fact
that at later stages of disease, the majority of leukemia-speciﬁc
T cells have been exhausted and deleted.8 Numerous leukemia-
associated antigens (LAAs) are expressed by human CML cells
that may be used for adoptive immunotherapy.16 However,
not all of these antigens are expressed by LSCs. Stem-cell
enriched cells from CML patients preferentially express the
LAAs Wilms tumor protein (WT-1) and PRAME, but not
proteinase 3, survivin or human telomerase (hTert).16 Therefore,
WT-1 and PRAME may represent promising therapeutic
targets for CTL-based immunotherapy in combination with
αPD-1-treatment to eliminate LSCs.
Figure 1. (a,b and d) H8 CML mice were either left untreated (Ø, n= 7) or treated with 5× 106 MACS-puriﬁed IFNγ–competent (p14, n= 7)
or –deﬁcient (p14xIFNγ− /−, n= 3) effector CTLs 17 days after CML induction. Two days later, PD-L1 expression in lin−BCR-ABL1-GFP+ BM CMPs
(c-kithiCD127−CD34+FcγR−), GMPs (c-kithiCD127−CD34+FcγR+), MPP2s (c-kithiCD135−CD48+CD150−), MPP1s (c-kithiCD135−CD48+CD150+),
ST-LSCs (c-kithiCD135−CD48−CD150−) and LT-LSCs (c-kithiCD135−CD48−CD150+) was determined by FACS. (a) Representative FACS plot of
PD-L1 expression on ST- and LT-LSCs from untreated or p14-treated H8 CML mice. (b) Fold change of MFIs of PD-L1 on LSC subsets versus no
treatment (n= 3–7 mice per group). Dotted line represents untreated H8 CML mice. (c) IFNγRα chain on CML progenitors (lin−c-kit+Sca-1−) and
LSCs (lin−c-kithiSca-1+) of n= 6 mice is shown. (d) Primary H8 CML mice were treated with p14 CTLs as described in a starting 17 days after
transplantation. Two days later the expression of indicated inhibitory markers on CD8+ T cells in the BM was analyzed. Values represent the
fold change in MFI versus untreated controls (n= 4–5 mice per group). (e) Spleen weights and numbers of (f) CMPs, (g) GMPs and (h) LSCs
were determined in lin−BCR-ABL1-GFP+ BM of H8 CML mice treated with rat-IgG (Veh, 200 μg intraperitoneally every third day), 3 × 106 FACS-
puriﬁed p14 effector CTLs (p14), PD-1-deﬁcient p14 effector CTLs (p14xPD-1− /−), anti-PD-1 mAb (αPD-1, 200 μg intraperitoneally every third
day, clone: RMP1–14) alone or in combination with effector p14 T cells (αPD-1/p14) starting 17 days after CML induction. (i) Equal numbers of
lin− cells were plated in methylcellulose and BCR-ABL1-GFP+ colonies were enumerated 7 days later by inverted ﬂuorescence microscopy.
(j) 5 × 106 BM cells from H8 CML mice were transplanted into lethally irradiated (2 × 6.5 Gy) recipient mice and survival was monitored. Pooled
data from two independent experiments with n= 6–9 mice per group are shown. (k) Kaplan–Meier survival curves of H8 CML mice treated as
described in e–h. Pooled data from two independent experiments with n= 4–7 mice per group are shown. (l) Frequency of BCR-ABL1-GFP+
granulocytes in peripheral blood and (m) BCR-ABL1-GFP+ colonies in lin− BM from H8 CML mice that were alive 90 days after CML induction.
(n) Survival of lethally irradiated (2 × 6.5 Gy) secondary recipients that were injected with 1× 107 BM cells from surviving αPD-1/p14- and
p14xPD-1−/−-treated primary CML mice (n= 4–6 mice per group). (k, n) Numbers of mice that succumbed to CML of total transplanted mice
are indicated. Data are displayed as mean± s.e.m. Statistics: (c) Student’s t-test, (e–i) one-way analysis of variance, (j and k) log-rank test.
*Po0.05, **Po0.01, ***Po0.001.
Letters to the Editor
1783
© 2015 Macmillan Publishers Limited Leukemia (2015) 1779 – 1797
Figure 2. (a–g) CB/6 CML mice (n= 4 mice per group) were treated either with rat-IgG (Veh, 200 μg intraperitoneally every third day), 8 × 106
MACS-puriﬁed CD8+ T cells from BL/6 mice (CD8), αPD-1 mAb (αPD-1, 200 μg intraperitoneally every third day) alone or in combination with
BL/6 CD8+ T cells (αPD-1/CD8) starting 11 days after CML induction. Ten days later, lin−BCR-ABL1-GFP+ BM was analyzed for (a) LSCs (c-kithiSca-
1+), (b) LT-LSCs (c-kithiCD135−CD48−CD150+), (c) ST-LSCs (c-kithiCD135−CD48−CD150−), (d) leukemia MPP1s (c-kithiCD135−CD48+CD150+) and
(e) leukemia MPP2s (c-kithiCD135−CD48+CD150−). (f) Equal numbers of total lin− cells were plated in methylcellulose and BCR-ABL1-GFP+
colonies were enumerated 7 days later by inverted ﬂuorescence microscopy. (g) Primary CB/6 CML mice were treated as described in a
starting 11 days after transplantation. Ten days later, 5 × 106 BM cells were transplanted into lethally irradiated (2 × 6.5 Gy) recipient mice (n= 4
mice per group) and survival was monitored. (h and i) Primary CB/6 CML mice were treated as described in a starting 11 days after
transplantation (n= 5 per group). (h) Numbers of BCR-ABL1-GFP+ granulocytes/μl blood and (i) Kaplan–Meier survival curves (n= 5 mice per
group). (j) BCR-ABL1-GFP+ colonies in lin− BM and (k) survival of lethally irradiated (2 × 6.5 Gy) secondary recipients (n= 4 mice) that received
1× 107 BM cells from αPD-1/CD8-treated primary CML mice that were alive 90 days after CML induction. (i, k) Numbers of mice that
succumbed to CML of total transplanted mice are indicated. Data are displayed as mean± s.e.m. Statistics: (a–f) one-way analysis of variance
(ANOVA), (g, i) log-rank test, (h) two-way ANOVA. *Po0.05, **Po0.01, ***Po0.001.
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Cellular origin of prognostic chromosomal aberrations
in AML patients
Leukemia (2015) 29, 1785–1789; doi:10.1038/leu.2015.30
Acute myeloid leukemia (AML) represents an aggressive cancer
entity, whose malignant cells respond abnormally to regulatory
stimuli and have lost the ability to differentiate and become fully
mature blood cells.1,2 AML evolves through accumulation of
independent genetic aberrations, including chromosomal structural
rearrangements and single nucleotide variants (SNVs). Conventional
AML diagnostics and recent seminal next-generation sequencing
(NGS) studies have identiﬁed more than 200 recurrent genetic
aberrations presenting in various combinations in individual
patients.1,3–7 Signiﬁcantly, many of these aberrations occur in
normal hematopoietic stem and progenitor cells (HSCs/HPCs)
before deﬁnitive leukemic transformation through additional
acquisition of a few (that is, mostly 1 or 2) leukemia-promoting
driver aberrations.5 NGS studies on sorted bone marrow (BM)
populations of AML patients with a normal karyotype have
demonstrated the presence of prognostic driver aberrations (that
is, NPM1, FLT3-ITD and FLT3-TKD) in committed HPCs but not in
multipotent HSCs.8–10 However, the HSC populations lacking the
prognostic driver aberrations contained preleukemic clones harbor-
ing a series of recurrent molecular aberrations that were present in
the fully transformed committed HPCs together with the prognostic
driver aberration.8,10,11 Adding to this vast heterogeneity and
complexity of AML genomes and their clonal evolution, a recent
study of a murine AML model demonstrated that t(9;11) AML
originating from HSCs responded poorly to in vivo chemotherapy
treatment as compared with t(9;11) AML originating from HPCs.12
Hence, recent advances in genetics support that AML is initiated
and sustained by a few aberrations that, in concert with their
cellular origin, deﬁne the leukemic phenotype of AML patients and
ultimately clinical outcome following conventional chemotherapy.
In the present study we examined the variegation among AML
patients with prognostic chromosomal driver aberrations with respect
to (i) the cellular composition of their HSC/HPC compartment, (ii) the
cellular origin of their ‘driver’ aberrations and (iii) the expression of
aberrant transcriptional programs as compared with normal.
For this, we applied an integrative experimental strategy
combining ﬂow cytometry-based immunophenotyping, as well as
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